BioNTech’s Clinical and Corporate Overhaul: Cancer Data Improves as COVID Era Ends

FierceBiotechAlumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospects

LabiotechFreeze variability, not progress: strengthen your cell therapy supply chain from the start

Endpoints NewsSupreme Court preserves mail access for abortion pill

FierceBiotechAardvark to dig into phase 3 data early after FDA imposes hold

Siemens HealthineersSiemens Healthineers Wins Key US Clearances As Valuation Gap Widens - simplywall.st

BioNTechBioNTech’s Clinical and Corporate Overhaul: Cancer Data Improves as COVID Era Ends - AD HOC NEWS

Every GreenBiotech Just Hit Fast Forward. Is Europe’s Seed Sector Ready? - seedworld.com

IQVIAIQVIA And Kexing Biopharm Advance Global Biosimilar Expansion Through AI Enabled Strategic Collaboration - BioPharma APAC

IlluminaCorvex Funds tied to Illumina (NASDAQ: ILMN) sell shares and partly unwind equity swaps - Stock Titan

FierceBiotechChutes & Ladders—AC Immune CEO bids adieu

Eli LillyIs Eli Lilly Going To $1,100? - 24/7 Wall St.

Clinical OMICsAI in Healthcare: Symposium Insights